May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Trabecular Micro-Bypass and Concurrent Cataract Surgery: 18 Month Analysis of the iStent
Author Affiliations & Notes
  • D. Spiegel
    Ophthalmology, Klinik Vincentinum, Augsburg, Germany
  • J. G. Feijoo
    Inst Ramon Castroviejo Univ and Hospital Clinico San Carlos, Madrid, Spain
  • J. M. Martinez de la Casa
    Inst Ramon Castroviejo Univ and Hospital Clinico San Carlos, Madrid, Spain
  • J. G. Sanchez
    Inst Ramon Castroviejo Univ and Hospital Clinico San Carlos, Madrid, Spain
  • GC-002 Study Group
    Ophthalmology, Klinik Vincentinum, Augsburg, Germany
  • Footnotes
    Commercial Relationships  D. Spiegel, Glaukos, C; J.G. Feijoo, None; J.M. Martinez de la Casa, None; J.G. Sanchez, None.
  • Footnotes
    Support  Study sponsored by Glaukos
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4192. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Spiegel, J. G. Feijoo, J. M. Martinez de la Casa, J. G. Sanchez, GC-002 Study Group; Trabecular Micro-Bypass and Concurrent Cataract Surgery: 18 Month Analysis of the iStent. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4192.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of a trabecular micro-bypass stent (iStent, Glaukos Corp.) in patients undergoing concurrent cataract and glaucoma surgery.

Methods: : Prospective, open-labeled, 24-month, multi-country evaluation of 48 patients with uncontrolled primary OAG and cataract. Patients underwent clear cornea phacoemulsification followed by gonioscopicallyab-interno implantation of the iStent. Ocular hypotensive (OH) medications were discontinued on the day of surgery. Forty-one patients completed 18 months and are included in this interim analysis. Primary outcome measures were reduction in IOP and subsequent reduction in OH medications.

Results: : At baseline, mean (±SD) IOP was 21.9 ± 3.98 mmHg on maximum tolerated therapy. At 18 months, mean IOP was 16.9 ± 3.24 mmHg, a 21.4% decrease (P < 0.001). At baseline, patients were taking a mean 1.7 ± 0.9 medications, by month 18 that had been reduced to 0.5 ± 0.74 (P < 0.001). At month 18, more than half the patients achieved an IOP ≤ 18 mmHg without requiring OH medications. The most commonly reported device-related adverse events were the appearance of stent lumen obstruction (7 eyes) and stent malposition (9 eyes), and most still achieved significant IOP reduction and reduction in drug burden. None of the adverse events were considered serious.

Conclusions: : The implantation of the iStent is safe and efficacious for reducing IOP in OAG patients and can help reduce or eliminate the number of glaucoma medications. A prospective randomized clinical trial (iStent placement vs. phacoemulsification alone) is under way in the USA as part of the FDA approval process.

Clinical Trial: : www.clinicaltrials.gov NCT00326014

Keywords: clinical (human) or epidemiologic studies: systems/equipment/techniques • intraocular pressure • cataract 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×